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Background. Type 2 diabetes (T2D) might occur within metabolic syndrome (MbS). One of the complications of T2D is an
impaired (imp) cardiovascular autonomic function (CAF). Aims. In subjects with T2D and age ≤ 55 years, the prevalence of
impCAF and its relationship with BMI, waist, HbA1c values, MbS, hypertension, and family history of T2D and/or hypertension
were analysed. Methods. 180 subjects consecutively undergoing a day hospital for T2D were studied. The IDF criteria were used to
diagnose MbS. To detect impCAF, 5 tests for the evaluation of CAF were performed with Cardionomic (Meteda, Italy). Univariate
and multivariate analyses were performed. Results. The prevalence of impCAF and MbS were 33.9% and 67.8%, respectively.
Among diabetics with impCAF, 86.9% had MbS. ImpCAF was signiﬁcantly associated with MbS, overweight, and HbA1c > 7%.
Both logistic (P = 0.0009) and Poisson (P = 0.0113) models showed a positive association between impCAF and MbS. The
degree of ImpCAF showed a positive linear correlation with BMI and HbA1c values. Conclusions. The study demonstrates that
glycaemic control and overweight inﬂuence CAF and that T2D + MbS is more strongly associated with impCAF than isolated
T2D. We suggest that MbS not only increases the cardiovascular risk of relatively young subjects with T2D but is also associated
with impCAF.
1.Introduction
Epidemiological studies demonstrated that diabetics display
a cardiovascular risk which is twice that of sex- and age-
matched nondiabetic population. In line with the high
cardiovascular risk of subjects with diabetes mellitus (DM)
are their frequent silent myocardial infarctions (MIs) [1, 2].
Clinically unrecognized MIs might be due to impaired
cardiovascular autonomic function (impCAF) which ﬁnally
evolves to cardiovascular autonomic neuropathy (CAN), a
chronic complication of both type 1 and type 2 DM. In
the Rochester diabetic neuropathy study concerning subjects
with T2D, no correlation was found between autonomic
symptoms and autonomic cardiovascular tests [3]. There-
fore, an analysis of cardiovascular reﬂexes with tests which
are sensitive and noninvasive allows to suspect diabetic
CAN.
In subjects with DM, cardiovascular risk is known to
be higher when clinical features of the metabolic syndrome
(MbS) are present along with DM [4]. Several reports show
that a higher cardiovascular risk is present in subjects dis-
playingaclusteroffactorspredisposingtotheatherosclerotic
cardiovascular disease and included in the syndrome named
MbS (Table 1)[ 5–7]. Subjects with T2D always have one of
the diagnostic criteria of MbS (glycaemia ≥ 110mg/dL), but
do not obligatorily show other diagnostic features for MbS.
In the present study we tried to assess whether MbS is more
frequently associated with ImpCAF in relatively young type
2 diabetics.
2. Aims
Our study evaluated the association, if any, between an early
deﬁcitofCAFandthepresenceofMbSdeﬁnedonthecriteria2 Experimental Diabetes Research
Table 1: Diagnostic criteria for the metabolic syndrome.
Any 3 of the following conditions
(1) Central obesity
According to NCEPIII∗
Country/ethnic group Sex Waist in cm
Any Male ≥102cm
Female ≥88cm
Or according to IDF†
Country/ethnic group Sex Waist in cm
Europids Male ≥94
Female ≥80
South Asians, Chinese Male ≥90
Female ≥80
Japanese Male ≥85
Female ≥90
(2) Elevated triglyceridemia (≥150mg/dL).
(3) Decreased HDL cholesterolemia (<40mg/dL in males, <50mg/
dL in females).
(4) Elevated arterial blood pressure (≥130/85mmHg).
(5) Elevated fasting blood glucose (≥110mg/dL or ≥100mg/dL
according to IDF†).
∗Adapted from the third report of the National Cholesterol Education
Program (NCEPIII) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III, ATP III).
†International Diabetes Federetion.
of the International Diabetes Federation (IDF) [6]a n d
whether any correlation existed between the detection of an
early deﬁcit of CAF and HbA1c, the duration of T2D and/or
hypertension (HBP), the occurrence of a positive family his-
tory of DM, HBP, or both, and the nutritional habits in a
cohort of type 2 diabetics not older than 55 years.
3. Methods
The study included subjects with T2D and age ≤ 55 years
consecutively undergoing a day hospital (DH) for chronic
complications of DM at the Unit of Endocrinology of the
University Hospital of Bari from October 2004 to September
2006. We screened 210 subjects. Thirty subjects out of
210 were excluded because they could not be screened for
cardiovascular reﬂexes (11 experienced acute MI less than
6 months before DH and the remaining 19 showed arrhyth-
miasatthebasalECGatDHadmission).180type2diabetics
(117 males and 63 females) with mean age of 48.62 ± 6.12
years (48.18 ± 7.26 and 48.86 ± 5.46 for female and males,
resp.) were recruited and underwent 5 diﬀerent tests for car-
diovascular reﬂexes. At DH admission, all subjects gave their
written informed consent. The tests included beat-to-beat
heartratevariation (DB),heartrateresponsetostanding (ly-
ingtostanding,LS),heartrateresponsetoValsalvamaneuver
(Vs), heart rate response to cough (cough test, CT), and
systolic blood pressure response to standing (PH) [1, 8–11].
All tests were performed with Cardionomic [8, 9], which is a
portable computerised system that is used for step-by-step
performance of several cardiovascular tests for autonomic
neuropathy. All tests were performed after an overnight fast
but never after overnight hypoglycaemia. Each subject was
instructed to refrain from smoking and drinking coﬀee at
least 8h before tests. Before the tests, patients were lying in
the supine position for 30 minutes and a basal ECG was per-
formed. As far as DB is concerned, it evaluates the physiolog-
ic arrhythmia induced by respiration and is an index of the
vagus nerve function. Inspiration induces pulmonary expan-
sion which stimulates stretch receptors in the lungs, in the
atrium, and in the chest wall. The above-mentioned recep-
tors stimulate the nucleus solitarius and the bulbar cardio-
inhibitory center through aﬀerent vagal ﬁbers. The ﬁnal ef-
fect is the inhibition of the vagus which is followed by the
heart rate increase. During expiration, opposite mechanisms
occur which induce heart rate deceleration. Therefore, res-
piratory arrhythmia is mainly due to the prevailing eﬀect of
the parasympathetic nervous system. When parasympathet-
ic autonomic dysfunction occurs, the respiration-induced
heart rate variation is decreased or abolished.
For DB, a parasympathetic test function, a 1min ECG
was performed when the subject was lying supine and deeply
breathed 6 times per minute. The expiration/inspiration R-R
ratio was calculated. For LS, a parasympathetic test function,
thepatientwasinvitedtostandsuddenlyandtheR-Rinterval
was measured at beats 15 and 30 after standing and the 30/15
ratio was calculated.
VS simultaneously evaluates parasympathetic, sympa-
thetic, and baro receptor functions. For VS, the patient
exhales for 15min into the mouthpiece of a manometer ex-
erting a pressure of 40mmHg. The ratio of longest-to-short-
est R-R interval was measured. For HP assessment, supine
systolic blood pressure was measured after the patient was
lying down for 30min and orthostatic blood pressure after
the patient was standing for 2 minutes. Orthostatic hypoten-
sion was diagnosed when the fall in systolic blood pressure
(SBP) levels was ≥30mmHg or that of diastolic BP (DBP)
was>10mmHginresponsetoaposturalchangefromsupine
to upright position [12]. Orthostatic hypotension is known
to reﬂect sympathetic dysfunction [13]. CT, a parasympa-
thetic test function, evaluates the cough-mediated increase
in heart rate. During the test, the patient was in the supine
position and ECG was performed when patient breathed for
15 seconds (basal) and again when he coughed 3 times. The
R-R ratio between the shortest R-R interval after the last
cough and the mean R-R interval during regular respiration
was calculated [10, 11].
Since for each test the range of normal values was chang-
ing with age, we elaborated a score grading from 0 (normal
responsetoallperformedtests)to5(impairedresponsetoall
performed tests). Normal values for tests were according to
Vespasiani et al. [8] but were also conﬁrmed in a cohort of
age- and sex-matched control subjects selected in our region
(n = 130). Part of this cohort of controls was already used to
validate CAF tests in a cohort of subjects with β-thalassemia
[9]. Control subjects showed normal glucose tolerance
(normal fasting glucose circulating levels and HbA1c levels
< 5.9%), they did not display any of the diagnostic featuresExperimental Diabetes Research 3
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Figure 1: Distribution of diﬀe r e n ts c o r e so fi m p a i r e dC A Fi nt h e
cohort.
of the MbS, and they were not taking any pharmacological
treatment.
We also analysed whether any relationship existed be-
tween the detection of diﬀerent degrees of impCAF and the
presenceofMbSaccordingtotheInternationalDiabetesFed-
eration [6]. The nutritional habits were also assessed by a
dieticianthroughadietaryinterview.HbA1c wasmeasuredin
HPLC (Menarini Diagnostics). Total cholesterol, HDL cho-
lesterol, LDL cholesterol, and triglycerides circulating levels
were measured with speciﬁc Dimension clinical chemistry
systems (Siemens Healthcare Diagnostics Ltd.) which are in
vitro tests intended for the quantitative determination in
human serum or plasma.
3.1. Statistical Analysis. Data are expressed as mean ± SD or
%. Two-sided P values refer to the Mann-Whitney U test for
continuous variables and Pearson’s χ2 for categorical vari-
ables. Univariate and multivariate analyses for at least one
positive CAF test versus none and mean number of positive
CAF tests were, respectively, assessed with logistic and Pois-
son’s regression models. Results are expressed as odds ratios
(ORs)orrateratios(RRs)andtheir95%conﬁdenceintervals
(CIs). Two-sided P values less than 0.05 were considered
signiﬁcant. All the analyses were performed using SAS (Re-
lease 9.1, SAS Institute, Cary, NC, USA, 2002-2003).
4. Results
4.1. Prevalence of Impaired CAF. Patients’ characteristics of
the sample by number of positive tests for impaired cardio-
vascular autonomic function (CAF) are reported in Tables
2(a), 2(b), and 2(c). In our cohort 33.9% subjects (61 out of
180) showed at least one pathologic test for CAF. Among
female patients, 4.76% showed a pathological response to
DB, 20.6% and 9.5% showed pathological responses to Vs
and CT, respectively. Among male patients, 4.3% showed a
pathological response to DB, 6.84% to LS, 18% to VS, and
6.84% to CT. Among females, no subject showed a score
r a n g i n gf r o m3t o5 .S c o r e2w a sf o u n di n4 . 7 6 %a n d
score 1 in 31.7% of female subjects (Figure 1). Among male
subjects, nobody showed score 3 or 5 and less than 1%
(0.86%) had a score 4. The distribution of scores 1 and 2 was
comparable to that found in the female cohort since 28.2%
and3.4%ofmalesubjectsshowedscores1and2,respectively
(Figure 1).
4.2. Impaired CAF and Anthropometric and Metabolic Vari-
ables. When female diabetics were stratiﬁed for BMI classes,
we found 23.8% normal-weight, 30.16% overweight, 38.1%
obese (class 1 and 2), and 7.94% severe obese women (BMI
≥ 40Kg/m2)( Figure 2). Among male subjects, 25.64% were
normal-weight, 41.03% overweight, 30.77% obese (class
1 and 2), and 2.56% severely obese (BMI ≥ 40Kg/m2)
(Fig-ure 2). The prevalence of MbS in the presence of
impCAF was signiﬁcantly higher than that in the absence
of impCAF in both sexes (Figure 3). The distribution of the
diﬀerent components of the MbS in the male and female
cohort in the presence or in the absence of impCAF was
similar (Figures 4 and 5).
When subjects were stratiﬁed for both CAF score and
BMI classes, the presence of at least one pathologic test for
CAF showed a signiﬁcant positive correlation with BMI >
25Kg/m2 (P = 0.0227, Table 3). Subjects with at least one
pathologic test had BMI (P = 0.0032), waist circumferences
(P = 0.0146), triglycerides (P = 0.0089), and HbA1c (P =
0.0292) levels signiﬁcantly higher than those of subjects with
normaltests.Theoccurrenceeitherofoneormoreabnormal
tests was not signiﬁcantly associated with a positive FH for
DM and/or HBP or with a duration of T2D longer than 5
years. By contrast, the occurrence of at least one pathological
test was positively associated to the occurrence of HBP
(P = 0.0061), a waist value >94cm (according to IDF)
(P = 0.0146), and triglycerides ≥150 (P = 0.0089). In the
multivariate Poisson model, we considered the association
between the mean number of tests positive for impaired CAF
and age, sex, classes of BMI, FH of DM, and duration of
DM longer than 5 years (Table 4). A statistically signiﬁcant
association with the mean number of positive tests for
impaired CAF was found when MbS was considered as
dichotomous(P = 0.0018).Signiﬁcantassociationswerealso
found between the mean number of tests positive for im-
paired CAF and the occurrence of overweight (BMI between
25 and 30Kg/m2) and HbA1c > 7% (Table 4). With adjust-
ment for BMI classes, FH of diabetes, and/or hypertension,
there was still a signiﬁcant association between the mean
number of tests positive for impaired CAF and HbA1c > 7%
(Table 4). With additional adjustment for sex, signiﬁcant
associations of the mean number of tests positive for im-
paired CAF with HbA1c > 7% and the occurrence of MbS
were conﬁrmed (Table 4).
4.3. Impaired CAF, MbS, and Nutrient Intake. Signiﬁcant
associations were found between the mean number of tests
positive for impCAF and a lipid intake >30% (Table 3).
When patients were stratiﬁed according to a daily lipid
intake >30%, the occurrence of at least one pathologic4 Experimental Diabetes Research
Table 2: (a) Patients’ characteristics by number of positive CAF tests. (b) Patients’ characteristics by number of positive CAF tests. (c)
Patients’ characteristics by antidiabetic therapy.
(a)
Variable Category Number of positive CAF tests All P value
At least one None
N 61 119 180
Age 48.9 ±5.34 8 .5 ±6.54 8 .6 ±6.1 0.9372
BMI 31.6 ±7.32 8 .0 ±5.02 9 .2 ±6.1 0.0032
BMI class
<25 10 (16.4) 35 (29.4) 45 (25.0)
0.0227 25–30 21 (34.4) 49 (41.2) 70 (38.9)
≥30 30 (49.2) 35 (29.4) 65 (36.1)
Duration 6.0 ±5.96 .4 ±6.56 .3 ±6.3 0.9071
Duration ≥5 years
Not assessed 3 (·)5 ( ·)8 ( ·)
0.4557 No 34 (58.6) 60 (52.6) 94 (54.7)
Yes 24 (41.4) 54 (47.4) 78 (45.3)
Family diabetes No 11 (18.0) 23 (19.3) 34 (18.9) 0.8336
Yes 50 (82.0) 96 (80.7) 146 (81.1)
Family hypertension No 38 (62.3) 71 (59.7) 109 (60.6) 0.7324
Yes 23 (37.7) 48 (40.3) 71 (39.4)
Fibers 27.6 ±4.22 7 .8 ±4.02 7 .7 ±4.1 0.9747
HDL-cholesterol 39.1 ±10.14 2 .5 ±11.34 1 .3 ±11.0 0.0685
HbA1c 7.7 ±1.47 .3 ±1.57 .4 ±1.5 0.0292
HbA1c > 6.5%
Not assessed 1 (·)0 ( ·)1 ( ·)
0.0864 No 15 (25.0) 45 (37.8) 60 (33.5)
Yes 45 (75.0) 74 (62.2) 119 (66.5)
HbA1c > 7%
Not assessed 1 (·)0 ( ·)1 ( ·)
0.0299 No 25 (41.7) 70 (58.8) 95 (53.1)
Yes 35 (58.3) 49 (41.2) 84 (46.9)
Height 1.6 ±0.11 .7 ±0.11 .7 ±0.1 0.0429
Fibers >30g/diet
Not assessed 13 (·)2 2 ( ·)3 5 ( ·)
0.8568 No 26 (54.2) 51 (52.6) 77 (53.1)
Yes 22 (45.8) 46 (47.4) 68 (46.9)
Hypertension No 27 (44.3) 78 (65.5) 105 (58.3) 0.0061
Yes 34 (55.7) 41 (34.5) 75 (41.7)
Lipids >30%
Not assessed 13 (·)2 2 ( ·)3 5 ( ·)
0.0048 No 28 (58.3) 78 (80.4) 106 (73.1)
Yes 20 (41.7) 19 (19.6) 39 (26.9)
Metabolic syndrome No 8 (13.1) 50 (42.0) 58 (32.2) <0.0001
Yes 53 (86.9) 69 (58.0) 122 (67.8)
Data are expressed as mean ± SD or %. Two-sided P values refer to the Mann-Whitney U test for continuous variables and Pearson’s χ2 for categorical
variables.
(b)
Variable Category Number of positive CAF tests All P value
At least one None
M e t a b o l i cs y n d r o m es c o r e
1 3 (4.9) 13 (10.9) 16 (8.9)
0.0001
2 5 (8.2) 37 (31.1) 42 (23.3)
3 18 (29.5) 27 (22.7) 45 (25.0)
4 23 (37.7) 34 (28.6) 57 (31.7)
5 12 (19.7) 8 (6.7) 20 (11.1)
Proteins >15%
Not assessed 13 (·)2 2 ( ·)3 5 ( ·)
0.0838 No 24 (50.0) 34 (35.1) 58 (40.0)
Yes 24 (50.0) 63 (64.9) 87 (60.0)Experimental Diabetes Research 5
(b) Continued.
Variable Category Number of positive CAF tests All P value
At least one None
Glucides >55%
Not assessed 13 (·)2 2 ( ·)3 5 ( ·)
0.4146 No 6 (12.5) 8 (8.2) 14 (9.7)
Yes 42 (87.5) 89 (91.8) 131 (90.3)
Sex Female 23 (37.7) 40 (33.6) 63 (35.0) 0.5859
Male 38 (62.3) 79 (66.4) 117 (65.0)
Triglycerides 167.3 ±92.1 140.9 ±95.8 149.9 ±95.1 0.0089
Waist circumference 104.9 ±17.99 7 .8 ±12.6 100.2 ±15.0 0.0146
Weight 85.0 ±21.37 8 .1 ±14.78 0 .4 ±17.5 0.0597
Data are expressed as mean ± SD or %. Two-sided P values refer to the Mann-Whitney U test for continuous variables and Pearson’s χ2 for categorical
variables.
(c)
Antidiabetic therapy Sex Patients/total
Diet alone Male 34/117
Female 17/63
Diet + metformin Male 26/117
Female 25/63
Diet + sulphonylureas or glinides Male 15/117
Female 3/63
Diet + metformin+ Male 27/117
sulphonylureas or glinides Female 8/63
Diet + insulin (basal/bolus) Male 6/117
Female 6/63
Notes. (1) The remaining 4 female subjects out of 63 were treated either with Insulin (basal/bolus) plus metformin or with insulin (basal/bolus) plus
sulphonylureas or glinides plus metformin).
(2) The remaining 9 male subjects out of 117 were treated either with insulin basal plus glitazones and metformin or with insulin basal plus sulphonylurea
and metformin.
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Figure 2: Distribution of BMI classes in the cohort.
CAF test was signiﬁcantly associated to a lipid intake >30%
(41.7%atleastoneversus19.6%noneP = 0.0048)(Table 3).
In a univariate analysis, a signiﬁcant correlation was
found between the mean number of tests positive for
impaired CAF and a protein intake <15% and a lipid intake
>30%.However,inthemultivariateanalysisproteinandlipid
content does not predict impCAF (Table 4).
5. Discussion
The study of both micro- and macroangiopathic complica-
t i o n so fD Mi sc r u c i a lf o rb o t hp r o g n o s i sa n dt h e r a p e u t i c
strategy. Among chronic microangiopathic complications of
DM, CAN involves the cardiovascular branch of the auto-
nomic nervous system (ANS) [14–17]. Because of CAN,6 Experimental Diabetes Research
Table 3: Association between impaired CAF and anthropomentric
and metabolic variables.
BMI ≥ 24.9Kg/m2 P = 0,0032
Hypertension P = 0,0061
Waist > 94/80cm P = 0,0146
Tryglycerides > 150mg/dL P = 0,0089
HbA1c ≥ 7% P = 0,0299
Protein intake ≤15%/day P = 0,0838
Lipid intake > 30% P = 0,0048
Metabolic syndrome P<0,0001
BMI: Body mass index was calculated as Kg/m2.
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Figure 3: Prevalence of metabolic syndrome in the cohort in the
presence or in the absence of impaired CAF. Abbreviations: CAF+,
presence of impaired CAF; MbS+, presence of Metabolic syndrome;
MbS−, absence of metabolic syndrome. Notes. Sixty patients out of
1 8 0h a da ni m p a i r e dC A F .
diabetics might experience silent MI, silent hypoglycaemia,
and a high ASA risk during major surgery. ANS is anatomi-
cally poorly accessible, and few direct physiological tests are
available to study CAF. Therefore, some indirect clinical tests
are used as screening tests which detect deﬁcits of CAF on
the basis of heart responses to a simple stimulus [18]. In
subjects with pathologic screening tests, the diagnosis might
be completed with more sensitive techniques, but indirect
screening tests help to select candidate subjects for more
sophisticated analyses [18]. The diagnosis of CAN is usually
done when at least 2 screening tests display pathologivc
responses [18], but often when more than one test is already
impaired and the diagnosis of CAN is made is not possible to
reverse the situation. Vice versa sometimes early parasym-
pathetic neuropathy may improve. In a longitudinal study
Gotts¨ ater et al. [19] demonstrated that after 7–10 years some
subjects with parasympathetic neuropathy did not fulﬁll the
criteria for the diagnosis anymore. Therefore we thought to
consider as an early deﬁcit of CAF the detection of at least
one pathological test (score 1). CAF was analysed by utilizing
ﬁve diﬀerent tests. To each pathologic test, we gave score 1
to establish a grading of severity of impCAF. In our cohort of
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Figure 4: Distribution of diﬀerent components of the metabolic
syndrome in the female cohort in the presence or in the absence
of impaired CAF. Abbreviations: CAF+: presence of impaired CAF;
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Figure 5: Distribution of diﬀerent components of the metabolic
syndrome in the male cohort in the presence or in the absence of
impaired CAF. Abbreviations: CAF+: presence of impaired CAF;
CAF−: absence of impaired CAF.
relativelyyoungsubjectswithT2D,ascoreofimpCAFhigher
than 2 was luckily rare, but the prevalence of at least one
pathologic test was 33.9%. In two multicenter studies and
a population study of type 2 diabetics, the prevalence of
CAN was 16–22% [16, 20, 21] .T h ep r e v a l e n c ew ef o u n dw a s
slightly higher. However, in the above-mentioned studies, 2
screening tests (DB, LS) or 3 (DB, LS, PH) were used. By
contrast, in our small cohort, 5 tests were always performed
in triplicate thus increasing the sensitivity of tests. Concern-
ing MbS, in our young cohort, 65% subjects had MbS ac-
cording to IDF, but the prevalence of MbS among the
subjectsshowingatleastonepathologictestofCAFwasmore
than 85%. A signiﬁcant positive correlation between im-
paired CAF and MbS was conﬁrmed with two diﬀerent
models of multivariate analysis. It was previously assessedExperimental Diabetes Research 7
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anassociationbetweenparasympatheticdysfunction(patho-
logic cardiac response to DB) and some features of the MbS
according to the WHO [22–24]. However, to our knowledge
this is the ﬁrst report stating that MbS, according to the
criteria of IDF, is associated with a higher occurrence of an
early deﬁcit of CAF in a relatively young cohort of type 2
diabetics. In the same cohort, we also analysed the possible
associations between the single components of MbS and the
detection of an early deﬁcit of CAF. However, score 1 was
stronglyassociatedwithmostofthe components oftheMbS.
We found a signiﬁcant correlation between the occur-
rence of at least one pathologic test of CAF and a BMI > 25,
which supports the negative role played by overweight on
cardiovascularrisk.Thelinkbetweenthehighcardiovascular
risk of T2D and overweight might be explained considering
the negative eﬀect played by overweight on glycaemic con-
trol. In this line of evidence in our cohort, a signiﬁcant asso-
ciationwasfoundbetweenhighHbA1c valuesandCAFscore.
When subjects were stratiﬁed on HbA1c values higher or
lower than 7, a signiﬁcant association was found between
HbA1c > 7 and the occurrence of at least one pathologic test.
Many studies have already demonstrated that either an acute
or a chronic poor glycaemic control might help the appear-
ance of CAN [25–27]. From diﬀerent meta-analyses the
median value of mortality after 5 years was around 25% in
diabetics with CAN and 4% in diabetics without CAN.
If the diagnosis of CAN was based on the occurrence of
2 pathological tests, the relative risk of mortality was 3.5
[28, 29]. By contrast, an improvement in glycaemic control
improvesanearlydeﬁcitofCAForstopsitsprogression[25].
In studies utilizing heart rate variability as an index of CAF,
mild CAF abnormalities improved if HbA1c values decreased
from 9.5% to 8.4% [26].
Interestingly subjects showing impaired CAF also show
diﬀerent dietary habits as compared with subjects with nor-
mal CAF since they consume a higher daily fat intake (in-
creased consumption of saturated fat derived from cheese
and meet) as compared with diabetics with normal CAF. In
some reports it has already been stated [30] that in subjects
with MbS a Mediterranean-style diet (high content of whole
grains,fruits,vegetables,nuts,andolive oil)improveschron-
iclow-gradeinﬂammatorystate(reductioninserumconcen-
trations of C-reactive protein, interleukin 6, insulin resis-
tance,andimprovedendothelialfunctionscore)ascompared
toabalancedlow-fatdiet.Ourdatasuggestthatsubjectswith
impaired CAF and MbS chose a wrong diet even if they were
living in a Mediterranean area.
Unexpectedly no association was found between CAF
scoreandthedurationofdiabetes orapositive familyhistory
of DM and/or HBP. In other papers a strong association was
found between the duration of diabetes and CAN [23]. In
several studies both PH and decreased heart rate variability
are more frequent and evident 5 years after the diagnosis
of Diabetes [23]. However, the subjects of our cohort were
younger than those considered in previous studies and they
experienced a program of education to healthy life style to-
getherwithdrugs(glitazoneorinsulinanalogues)oflastgen-
eration since the onset of diabetes, thus showing a metabolic
memory better than that of subjects from previous studies.
The lack of association between any deﬁcit of CAF and
a positive family history of DM probably suggest that genetic
andfamiliarfactorsmightplayaminorinﬂuenceincompro-
mising CAF as compared with environmental factors such as
glycaemic control.
In conclusion, our data strongly suggest the role played
by glycaemic control (assessed on the basis of HbA1c values)
and overweight on an early deﬁcit of CAF. The more sig-
niﬁcantassociationbetweenMbSandimpairedCAFascom-
pared with isolated T2D might suggest that the presence
of MbS not only increases the global cardiovascular risk of
diabetics not older than 55 years but also accelerates the
appearance of a deﬁcit of CAF which additionally increase
cardiovascular risk.
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